Beutels Philippe, Jit Mark
Centre for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp 2610, Belgium.
Sex Health. 2010 Sep;7(3):352-8. doi: 10.1071/SH10018.
This commentary discusses key issues for health economic evaluation and modelling, applied to human papillomavirus (HPV) vaccine programs.
We outline some of the specific features of HPV disease and vaccination, and associated policy questions in light of a literature search for economic evaluations on HPV vaccination.
We observe that some policy questions could not be reliably addressed by many of the 43 published economic evaluations we found. Despite this, policy making on universal HPV vaccination followed shortly after vaccine licensure in many developed countries, so the role economic evaluation played in informing these decisions (pre-dating 2008) seems to have been fairly limited. For more recent decisions, however, economic evaluation is likely to have been used more widely and more intensively.
We expect future cost-effectiveness analyses to be more instrumental in policy making regarding vaccines covering more HPV types, therapeutic HPV vaccines, and novel diagnostic tests for biomarkers of HPV infection and disease integrated with cervical screening programs.
本评论讨论了应用于人类乳头瘤病毒（HPV）疫苗计划的卫生经济评估和建模的关键问题。
根据对HPV疫苗接种经济评估的文献检索，我们概述了HPV疾病和疫苗接种的一些具体特征以及相关政策问题。
我们发现，我们找到的43项已发表的经济评估中，许多都无法可靠地解决一些政策问题。尽管如此，在许多发达国家，疫苗获得许可后不久就出台了普遍接种HPV疫苗的政策，因此经济评估在为这些决策提供信息方面所起的作用（2008年之前）似乎相当有限。然而，对于最近的决策，经济评估可能得到了更广泛和更深入的应用。
我们预计，未来的成本效益分析将在涉及更多HPV类型疫苗、治疗性HPV疫苗以及与宫颈癌筛查计划相结合的HPV感染和疾病生物标志物新型诊断测试的疫苗政策制定中发挥更大作用。
